Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study

• Published in: Frontiers in pharmacology Vol. 14; p. 1154377
• Main Authors: Iurlo, A., Cattaneo, D., Consonni, D., Castagnetti, F., Miggiano, M. C., Binotto, G., Bonifacio, M., Rege-Cambrin, G., Tiribelli, M., Lunghi, F., Gozzini, A., Pregno, P., Abruzzese, E., Capodanno, I., Bucelli, C., Pizzuti, M., Artuso, S., Iezza, M., Scalzulli, E., La Barba, G., Maggi, A., Russo, S., Elena, C., Scortechini, A. R., Tafuri, A., Latagliata, R., Caocci, G., Bocchia, M., Galimberti, S., Luciano, L., Fava, C., Foà, R., Saglio, G., Rosti, G., Breccia, M.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 23.03.2023
• Subjects: chronic myeloid leukemia; low dose; outcome; Pharmacology; resistance; treatment-free remission; tyrosine kinase inhibitors; tyrosine kinase inhibitors; chronic myeloid leukemia; low dose; outcome; resistance; treatment-free remission

TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free remission (TFR) are quite scarce. We conducted a ret...